HIV infection is a multisystem disease and haematological abnormalities are among the most common complications of HIV. HIV associated haematological abnormalities seem to be dependent on the level of virus replication, as these abnormalities are severe in late stage AIDS patients with high viremia. These abnormalities reflect the underlying immune status and may be prevented or corrected by use of highly active antiretroviral therapy (HAART).
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BACKGROUND
Human Immunodeficiency Virus belongs to family of human retroviruses. HIV infection is marked by progressive decrease in the number of circulating CD4 + T helper cells, which over a period of years leads to immunological decline and death due to opportunistic infections and neoplasms. HIV causes the Acquired Immunodeficiency syndrome (AIDS) 1 (WHO, 1991) . AIDS is either characterized by the presence of a particular opportunistic infection or the CD4+ T lymphocyte count being <200/mm 3 or a combination of both (Kasthuri AS et al., 2006) 2 HIV infection is a multisystem disease and haematological abnormalities are among the most common complications of HIV (Dhurve SA et al., 2014) . 3 Haematological abnormalities such as impaired haematopoiesis, immune and non-immune mediated cytopenia and altered coagulation have been described in patients with HIV infection /AIDS (Kasthuri AS et al., 2006) . 2 Different classes of antiretroviral drugs act at different stages of HIV cycle. Combination of several typically three or four drugs are known as Highly active antiretroviral therapy (HAART).These drugs must be taken in combination in order to have lasting effect (Amegor O et al.,2009 ). 4 Immune reconstitution in AIDS patients after HAART has been reported in several countries (Dai yi et al; 5 WKBA O et al; 6 Huruy K et al 7 ) .
Aims and Objectives
The aim of the study was to evaluate the various haematological parameters in HIV patients and to compare the mean differences of selected haematological profile between baseline, after 6 months and 12 months.
METHODS
The present study was a one-year observational study conducted from 1 st October 2016 to 31 st September 2017 in Haematology wing of Postgraduate Department of Pathology Government Medical College, Jammu. One hundred patients, seropositive for HIV by ELISA were included in the study. Ethical clearance from the institutional ethical committee was obtained. These patients were observed in detail and complete data of each patient was prepared. Complete haematological evaluation including CD4 count was done. Blood collected in a sterile EDTA containing tube and processed following our established laboratory protocol and universal precautions as per guideline of National AIDS Control Organisation (NACO, India). Written informed consent was taken from all.
Inclusion Criteria
This was a prospective study and was conducted on newly diagnosed patients of HIV who were attending HIV/AIDS clinic.
Exclusion Criteria
 Pregnant women. 
Statistical Methods
Descriptive statistics were expressed as mean ± standard deviation and results on categorical measurements as numbers (%). Statistical analysis was done using SPSS 16.0 version, P <0.05 statistically significant. Table 2 shows the mean haemoglobin which at baseline (at the time of presentation) was 9.94 ± 1.76, after 6 months was 10.73 ± 1.60 and after 12 months was 11.61 ± 1.52 with p value of <0.0001 which shows that there was a statically highly significant increase in mean to 11.61 ± 1.52. Other parameters that showed statically significant difference in mean after 12 months of therapy was RBC count (p value <0.0001) and platelet count. However p value for total leukocyte count, absolute neutrophil count, absolute lymphocyte count was not statistically significant.
RESULTS
Haematological Parameters
Mean ± Standard Deviation p Value Baseline* (n=100) Statistically significant increase in mean haematocrit was also seen after 12 months of therapy (p value=0.001). Mean erythrocyte sedimentation rate at base line was 22.75 ± 22.28 (prior to HAART) which after 6 months of therapy was 17.31 ± 13.39 and after 12 months of therapy, there was a statically significant decrease in mean to 13.38 ± 13.38 with p value of 0.0001 (Table-3 ). MCV and MCH also showed corresponding increase in mean with the follow up period but it was not statically significant.
Mean ± Standard Deviation p Value Baseline (n=100) Anaemia was the most common haematological abnormality at the time of presentation in these patients. Among the total of 100 cases, 93 (93%) cases had anaemia and 7 (7%) cases had normal haemoglobin at the time of presentation.
After 6 months of therapy anaemia was seen in 87% of cases which reduced to 76% after 12 months of therapy. Anaemia was graded based on haemoglobin level into mild, moderate and severe anaemia ( Table-4 ). Mild anaemia was seen in 26% of males (Hb range 10-13 gm) and 15% of females (Hb range 10-12 gm) at the time of presentation, 28% males and 19% of females after 6 month of therapy and 34% of males and 18% of females were having mild anaemia after 12 months of therapy. Moderate anaemia (Hb range 7.0-9.9) was seen in 46% of patients at the time of presentation which reduced to 28% cases after 6 months of therapy and 10.31% cases at 12 months of therapy. Severe anaemia (Hb <7 gm) was seen in 6% of cases at the time of presentation which to 1% case after 6 months of therapy and no patient had severe anaemia after 12 months of therapy. Relation of anaemia with the duration of therapy was statistically significant (p<0.0001) 
Table 4. Haematological Abnormalities in HIV Infected Patients
Other haematological abnormalities detected were leucopenia in 2% of cases, neutropenia in 3% of cases, lymphocytopenia in 18% of cases and thrombocytopenia in 9% of cases at the time of presentation. RBC count was less than lower limit of normal in 28% of females and 49% of males at the time of presentation. Lymphocytopenia was reduced to 12% of cases after 6 months of therapy which further reduced to 7.22% of cases after 12 months of therapy. No case of neutropenia was detected after 6 months of therapy and 1 case was detected as neutropenia after 12 months of therapy. Three cases showed thrombocytopenia after 6 months of therapy six cases after 12 months of therapy (Table-5 
DISCUSSION
In present study, the result of data analysis obtained shows a predominance of males amongst 100 patients that is males constituted 58% (n=58) with male: female ratio of 1.38:1. Similar sex distribution results were obtained in studies of Mitra JK et al., 8 (2015) with a male to female sex ratio of 1.12:1 and Devi CS et al., 9 2016 with a male to female sex ratio of 1.9:1.
The patient age in the present study was from more than 16 years and 71% of the patients were in the age group of 21 to 40 years with mean age of 36.59 ± 9.12, which as per the fact is the sexually active part of life as well as highly productive age group. This is comparable with the findings of Mitra JK et al., 8 (2015) where majority of the patients 21 to 40 years. This is also consistent with the findings of Devi CS et al., 9 (2016), mean age of 39.8 ± 10.7. Parinitha SS and Kulkarni MH 10 showed similar results with mean age of 34.55 ± 9.63. In the present study compared to male age distribution, females were younger, 35.71% of them were between 21 to 30 years of age group.
Hematologic changes have been accepted as powerful determining predictors of morbidity and mortality in HIVinfected patients (Doukas MA, 1992) . 11 It has been demonstrated that severe anaemia is linked with faster rate of HIV disease progression (Mocroft A et al., 1999) . 12 Haematological abnormalities commonly encountered in HIV-infected individuals are anaemia, granulocyte disorders, thrombocytopenia, lymphomas, coagulopathies and vascular malignancies like Kaposi sarcoma. Although in majority of cases, haematological abnormalities are detected in middle or advanced stages of HIV infection, some of these like anaemia and thrombocytopenia have been reported to occur in early stages of HIV infection (Basu A et al., 1999) . 13 Anaemia is the most common cytopenia in HIV-infected individuals, occurring in 10-20% of patients at initial presentation and diagnosed in approximately 70 -80% of patients over the course of disease. The incidence is strongly related with the progression of the disease and is common in the symptomatic group (Spira TJ patients had mild anaemia and 7% patients had no anaemia. Overall frequency of anaemia in our study was comparable with other studies 9% cases had thrombocytopenia which in agreement with the study carried by Patwardhan et al., 24 (2002) who had found thrombocytopenia in 13% of the cases. Sullivan et al., 25 (1997) reported one year incidence of thrombocytopenia in 8.7% persons with one or more AIDS defining illness. We also observed leucopenia in 2% patients and neutropenia in 3% of cases. Neutropenia tend to occur concomitantly with anaemia, 10 to 30% of those with ARC may be neutropenic, this may progress to about three-quarters of those with AIDS (Zon et al., 1987) . 26 Lymphopenia was seen in 18% of the cases. Similar observations was made by Tripathi et al., 21 (2005) in 25.6% cases. All of these patients were followed after 6 months and 12 months of therapy and various haematological parameters were evaluated at these intervals. It is found that RBC parameters-haemoglobin, RBC count, haematocrit and MCHC showed statically significant improvement after 6 months and 12 months of therapy. MCV and MCH also showed improvement after 6 months and 12 months of therapy although it was not statically significant. This difference is probably due to improvement in these parameters after the initiation of HAART. Thulasi RR et al., 27 (2016) also found the incidence and severity of anaemia slightly higher among the patients not receiving antiretroviral therapy. Statically significant improvement was seen in platelet count after 6 months and 12 months of therapy. Other haematological parameters like total leukocyte count, absolute neutrophil count and absolute lymphocyte count did not show any significant improvement after 6 months and 12 months of therapy, the reason being toxicity of therapies for HIV or associated conditions. An autoimmune mechanism involving antigranulocyte antibodies and impaired granulopoiesis and any infiltrative process involving the bone marrow (infection, malignancy) has also been postulated (Donald W et al.,1998) .
CONCLUSION
 This study shows that there was improvement in all parameters in these patients and also in the stage of disease when they were followed for one year after the initiation of HAART.  So regular follow up and compliance of patient is of utmost importance in checking the progress of disease as well as ensuring better quality of life.  Hence early diagnosis, appropriate treatment, haematinics and nutritious diet are the key factors for longer survival and good quality of life.  At the same time, campaign for health education and preventive measures should be a continuous process so that the affected individual will come forward to these designated centers and avail the facilities.  Heath workers, social organisations and civil society should be educated so that they are aware of this permanent infection and take appropriate measures at all levels and this will help to overcome the social stigma attached to it.
